Amarantus Bioscience Holdings, Inc. AMBS Company Overview 

Stock Message Board http://investorshangout.com/search?q=AMBS&...mp;yt1=Go!

Amarantus Bioscience Holdings, Inc. AMBS Current Price and Quotes
0.074
Previous Close
0.059
Open
0.062

Daily Range
0.0875 - 0.0605
52wk Range
0.195 - 0.004

Volume
31,025,071
Dividend
N/A

Average Vol (3m)
4,308,018
Yield
N/A

Amarantus Bioscience Holdings, Inc. AMBS
Company Information
675 Almanor Ave.
Sunnyvale, CA 94085

Website: http://www.amarantus.com
Phone: 408-737-2734
Email: gerald@amarantus.com
Find us on:      

Amarantus Bioscience Holdings, Inc. AMBS
Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company is focused on developing unique products and proprietary technologies for the potential treatment and/or diagnosis of Parkinson's disease, Alzheimer's disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as tr...

More >>

Amarantus Bioscience Holdings, Inc. AMBS
Financial Reportings and Disclosures
Reporting Status U.S. Reporting: SEC Filer
Audited Financials Audited
Latest Report Jun 30, 2013 10-Q
CIK 0001424812
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Business Status Development Stage Company a/o Nov 19, 2012
Incorporated In: NV, USA
Year of Inc. 2008
Employees 3 a/o Nov 19, 2012
Company Officers/Contacts
Gerald E. Commissiong CEO, President, COO
Marc E. Faerber CFO, Treasurer, Secretary
John W. Commissiong CSO
Company Directors
Mark Benedyk
Gerald E. Commissiong
John W. Commissiong
Robert L. Harris
Company Notes
Formerly=Amarantus Bioscience, Inc. until 4-2013
Formerly=Amarantus Biosciences, Inc. until 12-2012
Formerly=Jumpkicks, Inc. until 6-2011
Service Providers
Auditor/Accountant
Silberstein Ungar, PLLC
30600 Telegraph Rd.
Suite 2175
Bingham Farms, MI, 48025
United States

Legal Counsel
Sichenzia Ross Friedman Ference LLP
61 Broadway
New York, NY, 10006
United States

Investor Relations Firm
LHA Inc.
800 Third Ave.
New York, NY, 10022
United States


Amarantus Bioscience Holdings, Inc. AMBS
AMBS Security Details
Share Structure
Market Value1 $34,112,073 a/o Aug 30, 2013
Shares Outstanding 460,973,956 a/o Aug 12, 2013
Float Not Available
Authorized Shares 1,000,000,000 a/o Nov 14, 2012
Par Value  0.001
Shareholders
Shareholders of Record 64 a/o Apr 26, 2013
Corporate Actions
Ex. Date Record Date Pay Date
Dividend (0.00) Jun 14, 2011 Jun 06, 2011 Jun 13, 2011
Security Notes
Capital Change=shs increased by 25 for 1 split. Ex-date=06/14/2011. Rec date=06/06/2011. Pay date=06/13/2011.
Short Selling Data
Short Interest 700 (-99.36%)
Aug 15, 2013
Significant Failures to Deliver  No
Transfer Agent(s)
VStock Transfer

Amarantus Bioscience Holdings, Inc. AMBS Recent News


Aug 29, 2013 Amarantus CEO to Present at the 2nd Annual European Investing and Partnering Summit in Helsinki
Aug 27, 2013 Amarantus Announces Two New Independent Peer-Reviewed Publications for MANF
Aug 20, 2013 Amarantus Strengthens Balance Sheet With Preferred Stock Transaction
Aug 14, 2013 Amarantus BioScience - “Ophthalmology: MANF's Orphan Strategy Coming into Focus in Retinitis Pigmentosa”
Aug 12, 2013 Amarantus Announces Positive Orphan Data for MANF in Retinitis Pigmentosa
Aug 11, 2013 OTC Daily Alert Stock Watch - Amarantus (OTCQB: AMBS )
Aug 6, 2013 Amarantus Issues Mid-Year President's Letter to Shareholders
Jul 11, 2013 Amarantus BioScience President and CEO Publishes New Blog Entitled “#C4CT Concussion Awareness Summit - The Emergence of mTBI in the Concussion Debate”
Jun 26, 2013 Amarantus to Present at OneMedForum New York on June 27
Jun 21, 2013 Amarantus to Evaluate LymPro Test as a Diagnostic and Prognostic for Chronic Traumatic Encephalopathy

12next >

Amarantus Bioscience Holdings, Inc. AMBS Financials
Period Ending Dec 31, 2012 Dec 31, 2011 Dec 31, 2010 Oct 31, 2010
Total Revenue - 224 192 -
Cost of Revenue - - - -
Gross Profit - 224 192 -
Operating Expenses
Research and Development 584 1,178 490 -
Sales, General and Admin. 3,506 2,786 924 57
Non-Recurring Items - - - -
Other - - - 1
Operating Income (4,090) (3,740) (1,223) (59)
Income From Continuing Operations
Add'l Income/Expense Items 473 315 94 -
Earnings Before Interest and Tax (3,617) (3,425) (1,128) (59)
Interest Expense 1,518 1,015 79 -
Earnings Before Tax (5,136) (4,440) (1,208) (59)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (5,136) (4,440) (1,208) (59)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (5,136) (4,440) (1,208) (59)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (5,136) (4,440) (1,208) (59)